Ozempic Study: Semaglutide 2.4 mg Promises a Brighter Future for Heart Health

Ozempic Study: Semaglutide 2.4 mg Promises a Brighter Future for Heart Health

Bagsværd, Denmark, 8 August 2023 – A groundbreaking announcement comes today from Novo Nordisk’s state-of-the-art labs. Their recent SELECT cardiovascular outcomes trial sheds new light on the benefits of semaglutide 2.4 mg, especially for those grappling with weight issues and heart health concerns.

A Peek Inside the SELECT Trial

The SELECT trial took a deep dive into the effects of once-weekly subcutaneous semaglutide 2.4 mg versus placebo, alongside standard care, to understand its role in preventing major adverse cardiovascular events (MACEs). Over a span of five eventful years, 17,604 adults aged 45 years and above, who had weight issues and an established track record of cardiovascular disease but no prior diabetes, participated.

The outcome? A whopping 20% decrease in the risk of MACE for individuals treated with semaglutide 2.4 mg, in comparison to a placebo. The criteria for this outcome included cardiovascular death, non-fatal heart attacks, or non-fatal strokes.

Semaglutide 2.4 mg: Safe & Effective

Rest assured, safety was not compromised. Semaglutide 2.4 mg’s profile in the SELECT trial aligns perfectly with its previous trials, ensuring trust and reliability.

Martin Holst Lange, the visionary executive vice president for Development at Novo Nordisk, expressed his enthusiasm. “The SELECT findings affirm the promise of semaglutide 2.4 mg. With no approved medications currently available that address weight management while also mitigating heart risks, this is a significant stride forward,” said Lange.

What’s Next on the Horizon?

Novo Nordisk has set its sights on seeking regulatory green lights to expand the label indication for semaglutide 2.4 mg (branded as Wegovy®) in both the US and EU territories in 2023. The comprehensive findings from SELECT will be unveiled at an esteemed scientific gathering later this year.

Wegovy®: A Beacon of Hope

For those unfamiliar, Wegovy® is a once-weekly subcutaneous treatment of semaglutide 2.4 mg. Tailored as an accompaniment to a balanced diet and consistent physical activity, it aims to aid weight management. With a rich history of transforming lives in the US, Denmark, Norway, and Germany, its potential is undeniable.

Novo Nordisk, a healthcare titan founded in 1923 in Denmark, stands at the forefront of combating diabetes and other chronic diseases. With an unwavering commitment to scientific innovation and disease prevention, they continue to light the path for better health worldwide. Stay updated on their relentless pursuit at novonordisk.com and their social media channels.

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.